Arianne Phosphate Inc (DAN): Up on this interview ?.....Hope you'...

Up on this interview ?.....Hope you're faring well !

nowwhat2 · 2024-01-23T20:24:41.2870000Z

Up on this interview ?.....Hope you're faring well ! https://www.youtube.com/watch?v=XbpGOzgOBHM https://cen.acs.org/energy/energy-storage-/Lithium-iron-phosphate-comes-to-America/101/i4 https://investorshub.advfn.com/uimage/uploads/2024/1/23/kjlesDAN_111_23_3y_up_25pct_BO.jpg

Play Episode

7min

Proactive - Interviews for investors

Altech Batteries Secures Key German Licensing Approval

Altech Batteries Ltd CFO Martin Stein talked with Proactive about the company’s recent milestone—securing final licensing approval for its CERENERGY battery plant in Germany. This approval marks a crucial step, allowing Altech to proceed with construction once financing is secured. Stein explained the significance of grid storage batteries in stabilising renewable energy supply and outlined the advantages of Altech’s sodium fluoride-based CERENERGY batteries. Unlike traditional lithium-based solutions, these batteries are fire-safe and free from critical minerals like lithium, cobalt, and graphite. Discussing financing, Stein highlighted Altech’s engagement with corporate advisors KPMG to secure equity and debt partners. He also noted potential government grants and subsidies in Germany, though political transitions have created some uncertainty. Despite this, Stein expressed confidence in securing funding, backed by offtake agreements for the plant’s first five years of production. With an estimated 18-24 month construction timeline, Altech aims to play a key role in Europe's transition to sustainable energy storage solutions. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications! #AltechBatteries #RenewableEnergy #GridStorage #BatteryTech #CERENERGY #EnergyStorage #SodiumIon #GreenTech #SustainableEnergy #ASX

Proactive - Interviews for investors

Polarean Imaging chief business officer on potential of Xenon MRI pharma trials

Polarean Imaging PLC chief business officer Alex Dusek talked with Proactive's Stephen Gunnion about the company’s latest expansion into pharmaceutical-sponsored trials. This new initiative involves a multinational trial utilising Polarean’s Xenon MRI technology to assist drug development for lung diseases. Dusek explained that traditional lung function tests, such as spirometry, are crude and highly variable, making trials costly and time-consuming. Xenon MRI offers a more sensitive measurement, reducing variability and allowing drug companies to conduct trials with significantly fewer patients. "If you're designing a trial, let's say it's 25 to 50 patients with Xenon, that would take you 250 to 500 patients with the more traditional measures," he noted. Polarean is providing pharmaceutical companies with imaging biomarkers and harmonised data analysis, streamlining drug development. The company is also establishing a network of clinical sites equipped with Xenon MRI, creating an ecosystem that benefits sponsors, trial sites, and Polarean itself. Dusek highlighted Polarean’s partnership with VIDA Diagnostics, a well-known name in lung drug development, to further enhance the impact of this initiative. For more insights into Polarean Imaging’s latest developments, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #PolareanImaging #XenonMRI #LungDisease #DrugDevelopment #ClinicalTrials #PharmaResearch #MedicalImaging #Biotech #HealthcareInnovation #Investing

Proactive - Interviews for investors

Imugene’s Azercell shows strong response in blood cancer

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

Proactive - Interviews for investors

Founders Metals extends high-grade gold discovery at Van Gogh with promising drill results

Founders Metals CEO Colin Paget joined Steve Darling from Proactive to discuss the latest assay results from preliminary drilling at Van Gogh, the newest high-grade gold discovery at the company’s Antino Gold Project in southeastern Suriname. Recent drilling returned an impressive 72.0 metres (m) of 2.29 grams per tonne (g/t) gold (Au), extending mineralization to approximately 200.0 m vertical depth. This follows the previously reported 28.5 m of 7.12 g/t Au interval from just 18 metres downhole. Paget emphasized that gold mineralization extends from the surface, through the saprolite zone, and into fresh rock at depth. Notably, Van Gogh represents a completely original discovery with no current or historical artisanal mining within 1.5 km of the target area, highlighting its untapped potential. Encouraged by continued success at both Van Gogh and Da Vinci, Founders Metals is prioritizing exploration in new, high-potential areas. Up to 50% of the company's 2025 drill program will be allocated to these high-priority targets, reinforcing its commitment to expanding the Antino Gold Project. Additionally, a fifth diamond drill is expected to be operational by mid-year, further accelerating exploration efforts. #proactiveinvestors #foundersmetalsinc #tsxv #fdr #otc #fdmif #vangogh #davinci #Antino Gold Project

Followers	233
Posts	48602
Boards Moderated	10
Alias Born	02/07/2012

Volume:	19,025
Day Range:	0.15 - 0.155
Bid:	0.15
Ask:	0.16
Last Trade Time:	1:51:25 PM EDT
Total Trades:	11

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

DAN Detailed Quote

Recent DAN News

More DAN News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent DAN News

Go Ad-Free